Neurolentech develops precision medicine solutions that utilize genetic and neurobiological data to create tailored treatments for individuals with neurodevelopmental disorders. The company focuses on improving patient outcomes for conditions such as autism and ADHD by providing targeted therapies based on unique biological profiles.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery for neurodevelopmental disorders (NDDs) is challenging due to the complexity and heterogeneity of these conditions, which include epilepsy, intellectual disability, severe autism, and motor disorders. Traditional drug development approaches often fail to address the unique genetic and neurobiological profiles of individual patients with NDDs. This results in limited treatment options and suboptimal outcomes for affected individuals and their families.
Solution
Neurolentech is developing precision medicine solutions to accelerate drug discovery for neurodevelopmental disorders. The company utilizes patient-derived neuronal models to identify potential drug targets for treating conditions like epilepsy, severe autism, and intellectual disability. By creating robust neuronal cell model systems, Neurolentech aims to identify new, druggable targets that can address the underlying causes of these disorders. Their approach involves close partnerships with clinicians and patient foundations to speed up the progress of drug discovery and develop effective treatment options tailored to specific patient profiles.
Target Audience
Neurolentech's primary target audience includes clinicians and patient foundations focused on neurodevelopmental disorders, as well as pharmaceutical companies seeking novel drug targets and therapies for these conditions.
Features
- Patient-derived neuronal models for drug target identification
- Proprietary platform for developing robust neuronal cell model systems
- Focus on epilepsy, severe autism, and intellectual disability indications
- Partnerships with clinicians and patient foundations to accelerate drug discovery